Exosomal LINC01106 From PRP-Treated ADSCs Alleviates Chondrocyte Inflammatory Injury by Sponging miR-34a-5p to...

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Molecular Biology

Background:

• Osteoarthritis (OA) involves progressive cartilage degeneration and chondrocyte injury, with limited disease-modifying treatments.
• Exosome-based cell-free therapies show promise for OA, but their active molecules need further definition.

Purpose of the Study:

• To investigate the therapeutic potential of adipose-derived stem cell (ADSC) exosomes pretreated with platelet-rich plasma (PRP) for osteoarthritis.
• To elucidate the role of LINC01106 within these exosomes and its molecular mechanism in chondroprotection.

Main Methods:

• ADSCs were treated with PRP to enrich exosomes for LINC01106.
• Exosomes were characterized, and LINC01106 levels were modulated.
• Chondrocytes stimulated with IL-1β were used to evaluate apoptosis, inflammation, oxidative stress, and matrix degradation.
• The LINC01106/miR-34a-5p/SIRT1 axis was analyzed using molecular assays.

Main Results:

• PRP pretreatment significantly increased LINC01106 in ADSC exosomes.
• LINC01106-rich exosomes reduced chondrocyte apoptosis, suppressed inflammatory cytokines (TNF-α, IL-6), alleviated oxidative stress, and decreased MMP-mediated matrix degradation.
• LINC01106 acted as a competing endogenous RNA for miR-34a-5p, upregulating SIRT1 expression.
• Exosomes inhibited NF-κB and MAPK pathways via SIRT1.

Conclusions:

• PRP-stimulated ADSC-derived exosomes possess significant chondroprotective properties.
• The LINC01106/miR-34a-5p/SIRT1 pathway is crucial for the therapeutic effects of these exosomes in OA.
• This exosome-based strategy offers a promising cell-free therapeutic avenue for osteoarthritis treatment.